Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer—phase 3 ASCENT study subanalysis

被引：0

作者：

Lisa A. Carey

Delphine Loirat

Kevin Punie

Aditya Bardia

Véronique Diéras

Florence Dalenc

Jennifer R. Diamond

Christel Fontaine

Grace Wang

Hope S. Rugo

Sara A. Hurvitz

Kevin Kalinsky

Joyce O’Shaughnessy

Sibylle Loibl

Luca Gianni

Martine Piccart

Yanni Zhu

Rosemary Delaney

See Phan

Javier Cortés

机构：

[1] University of North Carolina Lineberger Comprehensive Cancer Center,Department of General Medical Oncology and Multidisciplinary Breast Centre, Leuven Cancer Institute

[2] Medical Oncology Department and D3i,Department of Hematology/Oncology

[3] Institut Curie,Department of Medical Oncology

[4] University Hospitals Leuven,Division of Medical Oncology, Department of Medicine

[5] Massachusetts General Hospital Cancer Center,Medical Oncology Department

[6] Harvard Medical School,Department of Medicine

[7] Centre Eugène Marquis,Department of Medicine, Division of Hematology/Oncology, David Geffen School of Medicine

[8] Institut Claudius Regaud,Department of Medicine and Research

[9] IUCT-Oncopole,Medical Oncology

[10] University of Colorado Anschutz Medical Campus,Medical Oncology Department

[11] Oncologisch Centrum,Department of Biostatistics

[12] UZ Brussel,Department of Clinical Research

[13] Miami Cancer Institute,Department of Clinical Development

[14] University of California San Francisco Helen Diller Family Comprehensive Cancer Center,International Breast Cancer Center, Quirón Group, Barcelona

[15] University of California,undefined

[16] Los Angeles,undefined

[17] Jonsson Comprehensive Cancer Center,undefined

[18] Winship Cancer Institute,undefined

[19] Emory University,undefined

[20] Baylor University Medical Center,undefined

[21] Texas Oncology,undefined

[22] US Oncology,undefined

[23] Hämatologisch-Onkologische Gemeinschaftspraxis am Bethanien-Krankenhaus,undefined

[24] Gianni Bonadonna Foundation,undefined

[25] Institut Jules Bordet and l’Université Libre de Bruxelles,undefined

[26] Gilead Sciences,undefined

[27] Inc,undefined

[28] Gilead Sciences,undefined

[29] Inc,undefined

[30] Gilead Sciences Inc,undefined

[31] Universidad Europea de Madrid,undefined

[32] Faculty of Biomedical and Health Sciences,undefined

[33] Department of Medicine,undefined

[34] Madrid,undefined

[35] Vall d´Hebron Institute of Oncology (VHIO),undefined

来源：

npj Breast Cancer | / 8卷

关键词：

D O I：

暂无

中图分类号：

学科分类号：

摘要：

Patients with triple-negative breast cancer (TNBC) who relapse early after (neo)adjuvant chemotherapy have more aggressive disease. In the ASCENT trial, sacituzumab govitecan (SG), an antibody-drug conjugate composed of an anti-Trop–2 antibody coupled to SN-38 via a hydrolyzable linker, improved outcomes over single-agent chemotherapy of physician’s choice (TPC) in metastatic TNBC (mTNBC). Of 468 patients without known baseline brain metastases, 33/235 vs 32/233 patients (both 14%) in the SG vs TPC arms, respectively, received one line of therapy in the metastatic setting and experienced disease recurrence ≤12 months after (neo)adjuvant chemotherapy. SG prolonged progression-free survival (median 5.7 vs 1.5 months [HR, 0.41; 95% CI, 0.22–0.76]) and overall survival (median 10.9 vs 4.9 months [HR, 0.51; 95% CI, 0.28–0.91]) vs TPC, with a manageable safety profile in this subgroup consistent with the overall population. In this second-line setting, as with later-line therapy, SG improved survival over conventional chemotherapy for patients with mTNBC.

引用

共 46 条

[21]

Adel NG(2015)Current approaches in treatment of triple-negative breast cancer Cancer Biol. Med. 12 1067-511

[22]

Melvin JC(2012)Second-line bevacizumab-containing therapy in patients with triple-negative breast cancer: subgroup analysis of the RIBBON-2 trial Breast Cancer Res. Treat. 133 2245-2795

[23]

Yardley DA(2021)Second-line eribulin in triple negative metastatic breast cancer patients. Multicentre retrospective study: the TETRIS trial Int J. Med. Sci. 18 553-4013

[24]

Goldenberg DM(2014)Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies Breast Cancer Res. Treat. 148 397-undefined

[25]

Cardillo TM(2019)Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study Ann. Oncol. 30 499-undefined

[26]

Govindan SV(2021)Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial Lancet Oncol. 22 2784-undefined

[27]

Rossi EA(2010)American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer J. Clin. Oncol. 28 3997-undefined

[28]

Sharkey RM(2013)Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update J. Clin. Oncol. 31 undefined-undefined

[29]

Cardillo TM(undefined)undefined undefined undefined undefined-undefined

[30]

Goldenberg DM(undefined)undefined undefined undefined undefined-undefined

← 1 2 3 4 5 →